Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call
08 août 2019 14h16 HE
|
Ritter Pharmaceuticals, Inc.
Market research indicates an unmet need for better lactose intolerance treatments and interest from both patients and physicians in the RP-G28 drug profile LOS ANGELES, Aug. 08, 2019 (GLOBE...
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
02 juil. 2019 09h00 HE
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update
20 juin 2019 09h15 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 20, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
07 mai 2019 09h15 HE
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
06 nov. 2018 07h00 HE
|
Ritter Pharmaceuticals, Inc.
Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019...
Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance
27 juin 2018 07h00 HE
|
Ritter Pharmaceuticals, Inc.
Conference Call Today - June 27, 2018 at 4:30 p.m. ET LOS ANGELES , June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...